A multicentre, open-label, randomized, phase III study to evaluate the efficacy of Tarceva or comparator Alimta (pemetrexed) or Taxotere (docetaxel) in patients with histologically documented, advanced or recurrent (stage IIIB and not amenable for combined modality treatment) or metastatic (stage IV) non-small cell lung cancer who have experienced disease progression during platinum-based chemotherapy

Trial Profile

A multicentre, open-label, randomized, phase III study to evaluate the efficacy of Tarceva or comparator Alimta (pemetrexed) or Taxotere (docetaxel) in patients with histologically documented, advanced or recurrent (stage IIIB and not amenable for combined modality treatment) or metastatic (stage IV) non-small cell lung cancer who have experienced disease progression during platinum-based chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2017

At a glance

  • Drugs Erlotinib (Primary) ; Docetaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TITAN
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jan 2016 Results of pooled analysis of seven studies published in the Journal of Thoracic Oncology
    • 15 Nov 2012 Planned end date changed from 1 Nov 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top